AVBP vs GNLX
AVBP: Arrivent Biopharma is a clinical-stage oncology company advancing firmonertinib, an EGFR-targeted tyrosine kinase inhibitor for treating non-small cell lung cancer with uncommon mutations, toward pivotal Phase 3 approval. GNLX: Genelux is a late clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies designed to selectively kill tumor cells and trigger personalized anti-tumor immune responses.
Side-by-side fundamentals
| Metric | AVBP | GNLX | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $31.54 | $2.96 | |
| Market cap as of 2026-07-24 | $1.4B | $133M | |
| Net margin as of 2026-07-24 | n/a | -115587.5% | |
| Operating margin as of 2026-07-24 | n/a | -117650.0% | |
| ROE as of 2026-07-24 | -49.0% | -174.6% | AVBP higher |
| ROA as of 2026-07-24 | -45.4% | -123.6% | AVBP higher |
| Debt / equity as of 2026-07-24 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-24 | n/a | -91.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -91.0% | |
| Beta as of 2026-07-24 | 1.42 | 0.56 | |
| 1-year return as of 2026-07-23 close | +41.2% | -10.3% | AVBP higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.